Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir Monotherapy in HIV-1
NCT02275065Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bictegravir in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by Gilead Sciences. Primary endpoint: Time-Weighted Average Change From Baseline up to Day 11 in Plasma HIV-1 RNA. Started Oct 2014; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02275065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275065.